MassChallenge

MassChallenge is a global nonprofit startup accelerator headquartered in Boston, Massachusetts, established in 2009. It supports early-stage entrepreneurs across various industries, including technology, healthcare, and social impact, by providing mentorship, resources, and networking opportunities. With locations in Israel, Mexico, Switzerland, Texas, and the UK, MassChallenge connects high-potential startups with industry experts and investors to foster innovation and facilitate growth. The accelerator operates on a non-equity model, allowing entrepreneurs to maintain full ownership of their companies while benefiting from strategic partnerships and tailored training programs. Through its diverse initiatives, such as targeted accelerator programs like MassChallenge HealthTech and FinTech, the organization aims to drive impactful change and enhance the global innovation ecosystem.

Cait Brumme

Acting CEO

Nick Dougherty

Managing Director, MassChallenge HealthTech

Siobhan Dullea

CEO

Matt Lashmar

Managing Director

Camila Lecaros

Managing Director

Yonit Serkin

Managing Director

Devon Sherman

Founding Director, Head of MassChallenge FinTech

Michelle Williams

Vice President and Head of Texas Strategy

Past deals in Medical

Embryoxite

Non Equity Assistance in 2024
Embryoxite is a biotechnology company specializing in non-invasive diagnostic services for pre-implantation embryos in human-assisted reproduction. It operates a platform that combines artificial intelligence, metabolomics, embryo imaging, and clinical data to enhance embryo selection accuracy, thereby improving patient outcomes in fertility treatments.

CNS Therapy

Non Equity Assistance in 2024
CNS Therapy, they contribute to human well-being through mind-body therapy and the research, design, education, and sale of devices that alleviate chronic disease, restore health, and extend useful life. They are a spin off from the University of North Carolina (UNC). Their base technology is a patent pending approach to chronic pain which combines operant behavioral therapy with a proprietary device which enhances learning and resets the autonomic nervous system - called SET - Systolic Extinction Training. They are dedicated to providing long lasting pain relief to patients. Their unique combination of psychological training and electrostimulation helps chronic pain patients to starkly reduce or even eliminate their pain and allow them to return to their daily lives.

Xibus Systems

Non Equity Assistance in 2024
Xibus Systems, Inc. is a biotechnology company based in Somerville, Massachusetts, specializing in the development of microbiological analytics and testing tools. The company focuses on creating solutions that detect pathogens, allergens, and spoilage organisms in consumable products. By integrating materials science, biotechnology, and optics, Xibus Systems aims to provide quantitative and array-based testing capabilities that are both efficient and cost-effective. Their innovative technology is designed for high throughput and rapid results, while also featuring a roadmap for compact and handheld hardware options. This unique combination of proprietary materials and biological agents positions Xibus Systems to effectively address the growing demands for food safety and quality assurance in the market.

HeroSupport

Non Equity Assistance in 2024
HeroSupport is a medical device manufacturing company based in Veyrier, Geneva, established in 2019. The company specializes in creating personalized solutions that transform imaging and treatment tables into medical immobilization devices designed to enhance patient comfort during clinical procedures. By providing tailored support, these devices allow patients to receive prone breast radiotherapy without the need to adapt to the standard table setup. This innovation not only improves patient comfort but also aims to enhance the effectiveness and cost efficiency of cancer treatment for healthcare providers.

Astron Medtech

Non Equity Assistance in 2023
Astron Medtech is a medical technology company focused on improving patient outcomes in tendon repair. The company develops disposable minimally invasive surgical devices that significantly reduce recovery time from six months to four months. By utilizing less invasive and sustainable surgical techniques, Astron Medtech aims to enhance the efficiency of surgical services while providing better options for patients undergoing tendon repair procedures.

3D Orthobiologic Solutions

Non Equity Assistance in 2023
3D Orthobiologic Solutions is creating a 3D-printed scaffold that may be customized for healing and rebuilding bone in oral and maxillofacial surgery.

Anviron

Non Equity Assistance in 2023
Anviron is a company focused on developing advanced therapies for late-stage cancers. It employs a team of scientists, doctors, and clinicians who work collaboratively to address the challenges posed by difficult-to-treat cancers. By leveraging cutting-edge scientific research, Anviron aims to create innovative therapies that meet the unmet medical needs in oncology. The company's efforts are directed towards improving patient outcomes and transforming the landscape of cancer care.

Malama

Non Equity Assistance in 2023
Malama is a developer of a personalized support platform aimed at improving pregnancy-related health outcomes, particularly for individuals managing diabetes during pregnancy. The platform offers tools for tracking glucose levels and meal intake, helping users identify dietary triggers and trends. Additionally, it provides access to one-on-one coaching, facilitating the optimization of health throughout pregnancy. By delivering actionable insights, Malama empowers patients to enhance their health and well-being during this critical period.

CranioSense

Non Equity Assistance in 2023
CranioSense is bringing intracranial hypertension into the light by simplifying the diagnostic process across the clinical spectrum.

Taurus Vascular

Non Equity Assistance in 2023
Taurus Vascular is a medical device company dedicated to enhancing long-term outcomes for patients with aortic aneurysms. The company is focused on developing innovative technology aimed at transforming the standard of care for these patients. Its novel medical device is designed to eliminate the adverse effects of endoleaks and promote accelerated shrinkage of aneurysm sacs following endovascular aortic aneurysm repair (EVAR). By addressing these critical issues, Taurus Vascular aims to improve patient outcomes within the healthcare industry.

Lura Health

Non Equity Assistance in 2023
Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

Flagler Health

Non Equity Assistance in 2023
Flagler Health is a developer of clinical decision support software that transforms clinics into virtually vertical health systems. The company offers a platform that leverages patient data and clinical guidelines to assist physicians in identifying potentially beneficial procedures that may have been overlooked. By utilizing advanced AI technologies, Flagler Health recommends optimal treatment strategies based on individual patient data, enabling healthcare providers to deliver more comprehensive care. This approach aims to improve patient outcomes and enhance the overall efficiency of healthcare delivery.

Auspex Diagnostics

Non Equity Assistance in 2023
Auspex Diagnostics is an AI startup focused on enhancing cancer care through advanced diagnostic services. It utilizes machine learning algorithms to analyze the genomic information from patients' tumor samples. This analysis helps in accurately assessing the risk of cancer recurrence and the efficacy of various treatments. By providing valuable insights, Auspex Diagnostics enables oncologists and patients to make informed, data-driven decisions regarding personalized treatment plans, ultimately aiming to improve the overall quality of cancer care.

Stellate Therapeutics

Non Equity Assistance in 2023
Stellate Therapeutics is a private biotechnology company specializing in the development of small molecules derived from human gut bacteria to create personalized therapies for neurological diseases. The company focuses on addressing age-related neurological conditions, particularly through its research on the gut-brain axis. Stellate has developed a portfolio of drug candidates, including AMA-101, which aims to be a first-in-class therapy for Parkinson's disease. Through its microbiome-derived medicine platform, Stellate Therapeutics is engaged in comprehensive research and has established capabilities in discovery, screening, production, and diagnostic development, striving to provide effective treatments for neurological disorders.

Form Biologics

Non Equity Assistance in 2023
Form Biologics is a new platform technology for the injectable formulation of biologic medicines in order to make treatments more patient-friendly and efficacious.

True Concepts Medical Technologies

Non Equity Assistance in 2023
True Concepts Medical Technologies is a medical device company dedicated to reducing financial waste in the healthcare system while enhancing patient outcomes. Founded in 2017 and based in Centerville, Ohio, the company develops innovative, cost-effective technologies that aim to save billions of dollars annually. Its flagship products are designed to improve the accuracy of medical procedures, including contaminant-free blood culture collection for sepsis diagnosis and treatment solutions for sudden cardiac arrest. By leveraging clinical experience and the product development expertise of Pixel and Timber, True Concepts Medical Technologies creates devices that minimize human error, ensure consistent clinical delivery, and ultimately reduce healthcare costs.

XN Health

Non Equity Assistance in 2023
XN Health is a medical device company based in Texas, founded in 2021. The company specializes in developing healthcare devices aimed at improving the process of mechanical ventilation. Its innovative technology focuses on phrenic nerve stimulation, which induces diaphragm contractions during ventilation. This approach helps protect against diaphragm dysfunction in patients who are mechanically ventilated, ultimately enabling them to wean off the ventilator more quickly and safely.

KardioStatus

Non Equity Assistance in 2023
KardioStatus is a healthcare technology company that converts biometric data into personalized clinical treatments. Its platform, developed by leading physicians and engineers, creates unique biometric profiles for patients and provides tailored therapeutic recommendations, helping healthcare providers enhance patient outcomes, lower costs, and simplify decision-making processes.

Cellorama

Non Equity Assistance in 2023
Cellorama multipurpose devices, reagents, and processes are patent-pending and protect cell structure and integrity during many procedures. User-friendly and cost-effective devices are designed to minimize stressful stages in the laboratory while saving time and vital resources.

Lighthanded Enterprises

Non Equity Assistance in 2023
Lighthanded Enterprises specializes in the development of innovative medical technology aimed at diagnosing middle ear effusions, particularly otitis media with effusion (OME), which is common in children. The company has created a laser otoscope that enhances diagnostic accuracy by providing an additional illumination source. This technology enables healthcare professionals to achieve up to ninety percent accuracy in identifying OME during examinations. By improving the detection of chronic middle ear effusions, Lighthanded Enterprises empowers doctors to make more informed decisions regarding patient care and treatment referrals, ultimately addressing a significant issue that can impair children's hearing for prolonged periods.

SafeGuard Surgical

Non Equity Assistance in 2023
SafeGuard Surgical is a medical device company focused on improving surgical outcomes and patient safety. It develops innovative, resorbable products designed to enhance colonic anastomotic healing and stability during advanced surgical procedures. These include a resorbable intraluminal stent graft and an extraluminal resorbable graft, along with anvil cap extension arms. By employing these products, SafeGuard aims to reduce surgical complications, lower healthcare costs, and minimize patient recovery time, ultimately preventing mortality and morbidity associated with surgery.

Speratum Biopharma

Non Equity Assistance in 2023
Speratum is a biopharmaceutical company focused on microRNA-directed oncology therapies. The Company was founded in 2014 by Christian Marín-Müller, Ph.D. and is dedicated to the development of a patented treatment for pancreatic cancer based on the combination of tumor suppressive microRNA molecules and nanoparticle-based drug delivery technologies. The Company is currently entering the final stage of preclinical trials for the pancreatic cancer therapy, while simultaneously expanding the patent’s coverage to incorporate other types of cancer and non-cancer indications and illnesses and expanding its intellectual property (IP) portfolio with complementary technologies in the fields of nanotechnology, medical devices and veterinary medicine.

Pharmesol

Non Equity Assistance in 2023
Pharmesol is a clinical services platform focused on automating follow-up care for medications. It utilizes AI technology to streamline communication among pharmacy stakeholders, including patients, healthcare providers, and payers. By automating calls and messages, Pharmesol enhances engagement and support for both patients and doctors. The platform also emphasizes effective data management through recorded documentation, ensuring that personalized support is accessible 24/7. This approach aims to improve the overall experience of medication management and follow-up care.

Trove Health

Non Equity Assistance in 2023
Trove Health offers a platform designed to enhance access to patient data for patients, healthcare providers, and life sciences organizations. The company's primary focus is on clinical trial recruitment, where it aims to build a diverse and engaged database of consented participants. By efficiently identifying and recruiting patients who meet specific enrollment criteria across various geographies and therapeutic areas, Trove Health enables researchers to advance medical cures and therapies. Additionally, the platform empowers patients by allowing them to control and potentially monetize their health information while receiving tailored treatments.

Perfusion Medical

Non Equity Assistance in 2023
Perfusion Medical has an IV solution for tissue perfusion restoration developed at VCU of medicine and is being commercialized. They have the potential to be game changers in the treatment of severe blood loss. PEG-20k IV solution's main mechanism of action in treating severe hypovolemic shock is to increase tissue perfusion, allowing for the rapid transfer of oxygen into oxygen-depleted tissues and organs.

Oatmeal Health

Non Equity Assistance in 2023
Oatmeal Health is a pioneering virtual cancer clinic that focuses on delivering high-quality, patient-centered care through the integration of AI technology. The organization supports patients in Community Health Centers, Health Systems, and Imaging Centers by utilizing nurse practitioners and AI agents. Its services encompass a wide range of offerings, including lung cancer screenings, risk assessments, diagnosis, care navigation, and educational resources aimed at saving lives. By developing a multispecialty primary care and radiology platform, Oatmeal Health aims to enhance cancer screening and care for underserved populations, providing innovative virtual and on-site services. These services include AI-driven patient identification and matching, as well as AI-nodule risk assessments, ultimately empowering medical professionals to deliver preventative, image-based cancer screening at scale.

Hybridwerx

Non Equity Assistance in 2023
Hybridwerx enables clinicians to enter notes fast and focus on assisting patients.

Qonect

Non Equity Assistance in 2023
Qonect is a digital health platform that aims to make healthcare more affordable for individuals by providing immediate savings on medical and food expenses. It offers a free Digital Health Card, which grants users access to instant discounts on medical bills and medications. The platform also includes features such as medical emergency loans, electronic laboratory test reports, and appointment bookings. By focusing on financial assistance for medical emergencies, Qonect helps users manage their healthcare costs effectively, particularly for those who must pay out of pocket for their medical expenses.

Drizzle Health

Grant in 2023
Drizzle Health develops low-cost, high-performance tuberculosis and other bacterial disease diagnostics.

Dream Team Baby

Grant in 2023
Dream Team Baby is a leading infant and toddler sleep consulting business, operating for over a decade. Backed by a board of medical advisors, the company offers holistic sleep solutions, believing every child can learn to love sleep. Services include comprehensive sleep assessments, custom sleep plans, and intensive coaching, along with parent support and child behavior advice. Dream Team Baby works with families nationwide and has been featured on national media outlets like the Today Show.

Trainfes

Non Equity Assistance in 2023
TrainFES is a digital neuro-rehabilitation platform designed to assist individuals with paralysis in their recovery process. By offering a combination of rehabilitation orthopedic devices and a mobile application, TrainFES enables users to engage in effective therapies from the comfort of their own homes. This approach not only reduces the costs associated with traditional rehabilitation methods but also aims to deliver improved outcomes for patients. The platform specifically targets individuals with spinal cord injuries and those recovering from cerebrovascular accidents, providing tools that facilitate monitoring and enhance the quality of life for users facing physical disabilities.

Red Arrow Therapeutics

Non Equity Assistance in 2023
Developer of a healthcare technology designed to replace the traditional way of treating cancer treatment. The company aims to transform the traditional therapeutic into a next-generation therapy for cancer diseases by maximizing the drug potency with minimum toxicity, helping the healthcare sector to overcome systemic toxicity and exhibiting strong anti-tumor efficacy in various tumor models both as monotherapy and in combination with immune checkpoint inhibitors.

Elythea

Non Equity Assistance in 2023
Elythea is a technology company that develops a medical platform for obstetricians. This platform uses machine learning and deep learning algorithms to predict the risk of pregnancy complications, such as postpartum hemorrhage, cesarean section, and eclampsia, as early as the first trimester. It leverages clinical history and demographic information available at the point of care, enabling doctors to prepare for potential high-risk cases months in advance. Elythea's proprietary models have shown significantly higher sensitivity in predicting hemorrhage risk compared to current gold standard assessments, potentially reducing mortality and healthcare costs by over 90%.

DocNexus

Non Equity Assistance in 2023
DocNexus is transforming the healthcare landscape by leveraging AI-powered knowledge graphs to enhance access to critical information. The company's platform provides a comprehensive database for key opinion leader (KOL) searches, advanced publication searches, and news aggregation, allowing medical affairs organizations to efficiently find evidence and stay updated on KOLs' digital presence. By delivering insights from millions of scientific publications, clinical trials, and news articles in seconds, DocNexus streamlines the process of connecting healthcare professionals across the ecosystem. This innovative approach enables clients to strengthen their medical affairs strategies and improve scientific exchange.

Aevice Health

Non Equity Assistance in 2023
Aevice Health specializes in non-invasive wearable technology aimed at monitoring respiratory health in real-time. The company develops devices specifically for asthmatic patients, which track and record vital historical data related to respiratory symptoms and medication usage. This technology facilitates the early detection of cardiopulmonary issues, enabling clinicians to monitor patient responses to treatment effectively. By providing critical health insights from the comfort of home, Aevice Health enhances patient care and allows for quicker, more targeted medical interventions.

Curespec

Non Equity Assistance in 2023
Curespec is focused on developing a medical device known as Nephrospec, aimed at addressing the interconnected challenges of chronic kidney disease and hypertension. The device is designed to preserve kidney function, thereby delaying the need for dialysis and treating high blood pressure. By providing healthcare professionals with an innovative tool, Curespec seeks to reduce the suffering associated with kidney failure and hypertension, ultimately improving patient outcomes in these prevalent health conditions.

Narval

Non Equity Assistance in 2023
Narval is a biotechnology company specializing in the development of synthetic antibody mimetic proteins (AMPs). These AMPs are significantly smaller than conventional antibodies, yet retain their biological functionality. They offer several advantages, including the ability to penetrate tissue barriers, generate limited immune reactions, target small and hard-to-reach antigens, and withstand heat. Narval's technology enables the creation of novel first-in-class immunotherapeutic drugs for diseases previously challenging to treat with monoclonal antibodies, such as respiratory, eye, and autoimmune conditions. The company leverages machine learning and artificial intelligence to optimize its drug development capabilities.

Symphony Biosciences

Non Equity Assistance in 2023
Symphony Biosciences is focused on developing innovative cancer therapies aimed at improving treatments for solid tumors, particularly targeting triple-negative breast cancer. This type of cancer currently has limited effective treatment options, primarily relying on toxic chemotherapies that often fail to provide significant survival benefits. By utilizing biomaterials in its research, Symphony Biosciences aims to enhance the immune response against these challenging cancers, ultimately providing healthcare professionals with better tools to treat patients. The company's mission is to improve patient access to effective cancer treatments and address the critical needs within oncology.

Eztia

Non Equity Assistance in 2023
Eztia specializes in the manufacturing of cold therapy wearables designed to provide effective and environmentally safe cooling solutions for users. Their products are portable and easy to apply directly to the skin, eliminating the need for refrigeration or batteries. These wearables safely reduce body temperature for extended periods without the risk of freezer burn associated with traditional ice packs. By contouring to the skin, Eztia's products offer a comfortable and practical option for individuals seeking relief from heat or discomfort, all at an affordable price.

PlusVitech

Non Equity Assistance in 2023
PlusVitech is a company dedicated to developing effective and safe therapeutic treatments and complementary diagnostic tests for cancer patients. It specializes in non-invasive genetic cancer detection, utilizing small molecules and monoclonal antibodies as alternatives to traditional tissue biopsies. This approach allows for earlier detection and treatment of cancers, thereby improving patient outcomes while minimizing discomfort and the time associated with invasive procedures.

SAFE4BOTH

Non Equity Assistance in 2023
SAFE4BOTH is a care strategy that supports moms with OUD and their substance-exposed child by promoting optimal prenatal and postpartum care and support. The platform supports moms in their recovery process by utilizing evidence-based treatment plans, case management, and behavioral health approaches.

Azooka

Non Equity Assistance in 2023
Azooka is a biotechnology company focused on manufacturing proprietary fluorophores and molecular biology products for life science research and molecular diagnostics. The company produces a range of fluorescent dyes and tags for applications involving DNA, RNA, chromosomes, and live cells, as well as molecular-grade sample collection and transport mediums. Azooka aims to provide secure and sustainable biotech consumables at affordable prices, making these essential tools accessible to researchers worldwide. Recently, the company was recognized as the "Best Women-Led Enterprise," highlighting its commitment to innovation and leadership in the biotech sector.

SensArs

Grant in 2022
SensArs is a medical equipment manufacturing company specializing in neuromodulation technology aimed at treating diabetic neuropathy. The company has developed an innovative implantable neurostimulator electrode designed to restore sensory feedback by delivering precise electrical impulses to the nerve fibers that transmit pain signals. This technology not only assists healthcare providers in enhancing patient functionality but also offers a long-term solution for pain management. SensArs' flagship system, SENSY, is particularly beneficial for patients with amputations or nerve damage, as it helps to restore natural sensations in their feet.

Wisedocs

Non Equity Assistance in 2022
Wisedocs provides a machine-learning software platform designed for insurance, legal, and independent medical evaluation firms to streamline the review of medical records. The platform addresses the challenges associated with unstructured medical data, catering to industries such as auto, liability, disability, workers' compensation, and tort law. By automating tasks like indexing and duplication detection, Wisedocs enhances the efficiency of document processing workflows, leading to improved accuracy and faster outcomes for clients. Its solution is designed for easy integration, allowing firms to simplify their back-office operations and reduce error rates in managing medical records.

Card Medic

Non Equity Assistance in 2022
CardMedic is a healthcare platform designed to enhance communication between healthcare staff and patients, addressing various barriers such as language differences, visual and hearing impairments, cognitive challenges, and literacy issues. The platform features a comprehensive library of digital flashcards that replicate clinical conversations on common healthcare topics. These flashcards are available in multiple formats, including multilingual options, sign language, easy-to-read text, and read-aloud capabilities. By facilitating clearer communication, CardMedic aims to improve the quality of care and reduce health inequalities, ensuring that patients can access essential healthcare information in a way that is understandable to them. The platform is accessible via smartphones, tablets, or desktops, making it a versatile tool for both patients and healthcare providers.

Oculogenex

Non Equity Assistance in 2022
Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.

SOAP Health

Non Equity Assistance in 2022
SOAP Health is a healthcare technology company based in Boca Raton, Florida, founded in 2019. It develops an artificial intelligence-powered platform designed to enhance physician productivity and improve patient outcomes. The platform captures and analyzes detailed patient data before medical visits and integrates with electronic health records to streamline clinical practice. By utilizing a conversational interface, it simplifies patient-reported data collection and risk assessment, producing nearly complete SOAP notes to assist physicians in clinical decision-making. This approach not only helps identify at-risk patients and facilitates early disease detection but also aims to increase patient engagement and satisfaction while reducing errors and liability exposure for healthcare providers.

juli

Non Equity Assistance in 2021
juli is a digital healthcare startup founded in 2020, aimed at improving the lives of individuals with chronic conditions. The company develops an artificial intelligence-powered application that consolidates diverse healthcare data into a single platform. This application supports users dealing with various chronic health issues, such as asthma, migraines, depression, bipolar disorder, and chronic pain. By integrating data from smartphones, wearables, and self-reported information, juli enables users to self-track and manage their symptoms effectively. The founders, motivated by personal experiences with chronic conditions, leverage their expertise in big data to enhance healthcare outcomes and promote better understanding of health triggers and management strategies.

Eupnoos

Non Equity Assistance in 2021
Eupnoos is a health-tech company specializing in digital healthcare solutions for lung health and disease detection. The company has developed a smartphone-based application that utilizes the device's microphone and camera to perform clinical-grade lung function tests and symptom-guided assessments. This platform enables users to screen, measure, and track the progression of lung health issues. By providing device-agnostic, API-accessible automated testing and data interpretation, Eupnoos supports both clinical and consumer-grade respiratory monitoring devices. The company's services facilitate telehealth and remote patient monitoring, empowering individuals to gain insights into their lung health and access professional healthcare guidance.

Delfina

Non Equity Assistance in 2021
Delfina is a company that specializes in developing a personalized prenatal care system aimed at ensuring the safety of mothers and infants during pregnancy. By leveraging data and machine learning, Delfina's platform creates individualized pregnancy care plans that assess patient risk through various metrics. This approach not only enhances interventional workflows but also improves provider efficiency, facilitating early intervention in prenatal care. Delfina's commitment to data-driven insights is paving the way for clinical innovation, ultimately striving to deliver equitable and cost-effective healthcare solutions for expectant families.

Patientory

Non Equity Assistance in 2021
Patientory, Inc. is a healthcare technology company based in Atlanta, Georgia, established in 2015. It offers a health data management platform that enables individuals to securely store, manage, and share their health information. The platform empowers patients to take control of their medical records and chronic illness management while facilitating better communication and support between healthcare providers and patients. By integrating a blockchain-enabled network, Patientory streamlines access to health data, enhances care coordination, and provides insights into health outcomes. This approach aims to democratize health data ownership, reduce healthcare costs, and improve overall patient engagement and health management.

Carium

Non Equity Assistance in 2021
Carium is a developer of an individualized healthcare platform that enhances the management of health and wellness journeys for users. The platform aims to deliver a personalized, actionable, and efficient care experience for both healthcare providers and their clients. By integrating augmented data from daily life, Carium equips care teams with the insights necessary to make informed clinical decisions. This approach not only fosters improved health outcomes but also helps reduce costs for healthcare providers and payers. As a result, Carium's platform contributes to better overall satisfaction for both care teams and the individuals they support.

Together by Renee

Non Equity Assistance in 2021
Together by Renee is a free app that uses generative AI to streamline and automate health tasks like ordering refills, booking appointments and completing forms in an easy user experience perfect for the 123 million aging Americans managing diabetes, obesity, hypertension, and more. Together measures vital signs like blood pressure via smartphone camera - with no devices or wearables required. Together requires no data entry, typing or integration to legacy systems, using just AI to automate patient-centric care coordination. 67% of Together’s first 15,000 users are over 55 years of age and Together enjoys NetPromoter score of +85.

Ferrum Health

Non Equity Assistance in 2021
Ferrum Health, Inc. is a health technology company based in Santa Clara, California, that develops an artificial intelligence platform aimed at preventing medical errors and improving patient outcomes. The platform analyzes patient data across health systems to identify gaps in care and deploys multiple computer vision algorithms to evaluate radiologic images for commonly overlooked pathologies, such as lung nodules and fractures. Additionally, a proprietary natural language processing algorithm correlates these findings with physician notes, enabling hospital quality officers to address potentially missed diagnoses. Founded in 2017, Ferrum Health focuses on ensuring quality assurance in critical healthcare decisions, thereby enhancing the overall patient care experience through the integration of AI-driven tools.

miniMarrow

Non Equity Assistance in 2021
miniMarrow presents a new disruptive therapeutic approach for the in-situ production of blood components in leukemic patients to replace weekly and burdensome transfusions markedly increasing patient quality-of-life. miniMarrow is operating in stealth mode. miniMarrow was established in Renens, Vaud

Card Medic

Non Equity Assistance in 2021
CardMedic is a healthcare platform designed to enhance communication between healthcare staff and patients, addressing various barriers such as language differences, visual and hearing impairments, cognitive challenges, and literacy issues. The platform features a comprehensive library of digital flashcards that replicate clinical conversations on common healthcare topics. These flashcards are available in multiple formats, including multilingual options, sign language, easy-to-read text, and read-aloud capabilities. By facilitating clearer communication, CardMedic aims to improve the quality of care and reduce health inequalities, ensuring that patients can access essential healthcare information in a way that is understandable to them. The platform is accessible via smartphones, tablets, or desktops, making it a versatile tool for both patients and healthcare providers.

Oculogenex

Non Equity Assistance in 2021
Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.

Ostiio

Non Equity Assistance in 2021
Ostiio is focused on developing an innovative bone distraction system aimed at correcting skeletal deformities and deficiencies. The company has created a fully implantable device that is buried beneath the patient's skin, eliminating the need for external components. This advanced system features a magnetically driven distraction mechanism that can be expanded with precision and monitored remotely by physicians. This programmability provides surgeons with enhanced transparency and control during the treatment process, addressing a longstanding challenge in skeletal correction. Ostiio operates as a company under the Penn Center for Innovation, emphasizing its commitment to advancing medical technology in orthopedics.

MyoGene Bio

Non Equity Assistance in 2021
MyoGene Bio focuses on creating innovative therapies for muscle diseases, with an initial emphasis on a gene-editing treatment for Duchenne muscular dystrophy. The company leverages advanced technologies to directly address the underlying causes of this condition, aiming to significantly improve disease progression. By targeting the fundamental issues associated with Duchenne muscular dystrophy, MyoGene Bio seeks to provide clinicians and patients with effective solutions that can lead to meaningful advancements in managing severe muscle disorders.

MediCircle

Non Equity Assistance in 2021
MediCircle is a healthcare technology company focused on improving access to cancer care by repurposing unused oral chemotherapeutics. The company collects leftover medications, ensures their quality, and redistributes them to patients in need, thereby addressing disparities in healthcare access. By leveraging financial waste within the healthcare system, MediCircle provides a safe and low-cost alternative to medication disposal. Their platform enables pharmacies to track the history and quality of each medication donation, including details on potency and purity. This innovative approach not only saves money for patients and insurance providers but also enhances the health of local communities by reducing pharmaceutical waste and making cancer treatments more accessible.

Davenport SAF-T Systems

Non Equity Assistance in 2021
Davenport SAF-T Systems is dedicated to enhancing the safety and independence of older adults through innovative technology. The company has developed a lightweight safety garment designed to prevent injuries while walking. This garment, which takes the form of a vest, is equipped with sensors that can detect an unrecoverable fall in progress. In response, a system of airbags activates within less than half a second, providing immediate protection to vulnerable areas of the body, such as the head, neck, shoulders, elbows, and hips. By focusing on injury prevention, Davenport SAF-T Systems aims to improve the quality of life for seniors and reduce the risks associated with falls.

Ronawk

Non Equity Assistance in 2021
Ronawk is a biotechnology company that specializes in the development of T-Block technology, which produces patient-specific biologics for the treatment of diseases, including cancer, organ injuries, and burns. The company has created a proprietary method for growing primary stem cells in a three-dimensional environment, allowing these cells to retain their essential characteristics outside the body. This innovative approach enables the rapid expansion of stem cells, making them suitable for early-stage diagnostics and the repair of injured tissues. Additionally, Ronawk focuses on preserving primary cells from patients for future use in reconstructive surgeries, thereby enhancing the efficiency and density of human cell growth for tissue generation and disease modeling.

Selmod

Non Equity Assistance in 2021
Selmod, based in Basel, Switzerland, specializes in developing innovative therapies aimed at treating life-threatening, multi-drug resistant infections. The company focuses on discovering and advancing small molecules and peptides that target new mechanisms of action, addressing the urgent need for effective treatments in hospital settings where first-line therapies have failed. Selmod aims to provide second-line and last-resort options through a disruptive approach that incorporates dual modes of action to overcome resistance mechanisms. The company's lead candidates, SLM500, SLM100, and SLM300, have shown promise in preclinical studies, with market projections indicating a total available market exceeding $9 billion. With an experienced leadership team skilled in advancing clinical candidates for major pharmaceutical companies, Selmod plans to utilize funding to advance three IND-enabling candidates and six lead-optimized candidates into proof-of-concept stages.

WestFace Medical

Non Equity Assistance in 2021
WestFace Medical is a medical device company focused on enhancing vascular access procedures through innovative imaging technology. Their flagship product, SingleStick™, features a patented imaging adapter that employs optical coherence tomography (OCT) to provide real-time visualization of needle trajectories during vascular access. The system consists of a disposable handheld imaging adapter that attaches to any hollow bore needle and an OCT image processor, which displays the captured images. This technology allows clinicians to visualize anatomical markers in real-time, thereby improving clinical outcomes and patient satisfaction while potentially reducing costs associated with vascular access procedures. By offering a solution that facilitates traditional techniques with advanced imaging capabilities, WestFace Medical aims to redefine the standard of care in this critical area of healthcare.

Netnoids Rx Laboratories

Non Equity Assistance in 2021
Netnoids Rx Laboratories operates a cancer contract research organization that uses patient-derived organoid model systems to help find a cure for rare cancers.

Agile Focus Designs

Non Equity Assistance in 2021
Agile Focus Designs automates and accelerates microscopic imaging with fast focus and zoom technology without any moving parts. This electronic control of true optical zoom and focus without complex algorithms revolutionizes the way microscopes can be used.

Galileo Innovations

Non Equity Assistance in 2021
Galileo Innovations develops human performance-optimizing biotech gear and equipment for athletes, first responders, military members, and labor industry workers. Its proposed technology, KordoFan, augments users with actionable insights concerning environmental and biometric hazards in real-time to target heat injuries; through an array of biomimicry cooling designs, the device aids in speed, agility, mental clarity, muscle recovery, strength, and stamina during training/shifts.

Newton Tech

Non Equity Assistance in 2021
Newton Tech specializes in mobile physiotherapy technology aimed at assisting stroke patients in their recovery. The company's flagship product, Mobi, provides individualized insights and real-time fall detection and prevention. By tracking patients' movements and recording their walking patterns, Mobi helps users develop a unique movement signature, which in turn offers personalized movement insights. Newton Tech's mission is to facilitate a healthier future for stroke survivors through innovative technology that enhances rehabilitation and promotes safety.

CaringWire

Non Equity Assistance in 2021
CaringWire is a digital health platform that enhances the healthcare experience for individuals, families, and businesses. It offers a unified virtual care ecosystem that includes a range of personalized services such as behavioral health, virtual primary care, online pharmacy, family planning, estate planning, and family caregiving. The platform aims to improve access to healthcare tools, allowing users to conveniently manage their health and wellness needs. Partnering with the University of Wisconsin School of Nursing, CaringWire ensures its services are grounded in the latest research, providing comprehensive guidance and support. The mission of CaringWire is to make healthcare more accessible and manageable, aspiring to be the primary digital solution for accessing trusted care.

Mutuus

Non Equity Assistance in 2021
Mutuus is a pioneering digital healthcare membership service in Mexico, providing a comprehensive range of healthcare solutions through an intuitive platform. The service emphasizes prevention, care, and the restoration of health while also safeguarding the assets of its members. Key features of the platform include the ability to book home appointments, track physical activity, receive healthy meal suggestions, and request ambulance services. Additionally, it offers continuous medicinal, nutritional, and emotional support, allowing users to complete their treatments at hospitals without incurring extra costs. By combining these various services, Mutuus aims to enhance the overall health and well-being of its members while ensuring affordability and accessibility.

MoviWear

Non Equity Assistance in 2021
MoviWear is a technology company that specializes in medical AI and remote monitoring solutions, primarily through its platform MoviWearMED. This platform is designed to monitor patients' vital signs in real-time, whether they are at home, in retirement facilities, or on the go. By utilizing proprietary 5G IoT NurtureWatch wearables, MoviWear can detect critical changes in health indicators such as heart rate, temperature, blood pressure, and oxygen levels, as well as alerting caregivers in case of falls. The company addresses the increasing demand for continuous health monitoring outside of traditional hospital settings, particularly for seniors. Founded in 2017, MoviWear aims to enhance patient safety and prevent health emergencies, drawing inspiration from a personal family experience. Its clientele includes health and telecommunications companies across North America, Europe, and Israel.

Labinnova

Non Equity Assistance in 2021
Labinnova detects Breast Cancer in a Breath Sample with 98% sensibility. providing Qualitative results.

LIALT Laboratorio de Investigación Alternativa

Non Equity Assistance in 2021
LIALT Laboratorio de Investigación Alternativa develops toxicological evaluations without the use of animals. LIALT replaces the use of animals through the use of three-dimensional tissues in conjunction with internationally recognized protocols that provide more specific information on the mechanisms of toxic action than that obtained in animals, offering a solution to the problem previously exposed.

Nightingale Caring Solutions

Non Equity Assistance in 2021
Nightingale Caring Solutions specializes in nursing care analytics aimed at enhancing the delivery of nursing services within healthcare systems. By employing advanced research techniques, big data, and machine learning, the company analyzes the relationship between individual nurses and patient outcomes. This analysis supports hospital administrators in optimizing various operational aspects, such as nurse staffing, scheduling, and nurse-patient assignments. The technology developed by Nightingale Caring Solutions enables stakeholders to visualize workforce dynamics and make informed decisions that improve both patient and nurse outcomes. Ultimately, the company focuses on creating tailored solutions that promote safety, efficiency, and cost-effective care delivery in the healthcare sector.

NurLabs

Non Equity Assistance in 2021
NurLabs develops label-free and reagent-free diagnostics to detect cancer early when it is most treatable.

ModoScript

Non Equity Assistance in 2021
ModoScript develops a B2B hardware SaaS solution focused on remote treatment monitoring and big data analytics to enhance medication and treatment protocol efficiency. The company specializes in high-cost specialty pharmaceuticals, particularly Oral Oncolytics, and aims to leverage treatment progress data to create more personalized and safer therapies. By targeting pharmaceutical companies, health insurance providers, and medical practices, ModoScript facilitates the delivery of remote treatment care for patients with cancer and other chronic conditions. Their customizable data analytics model allows for real-time assessment of treatment effectiveness while ensuring that patients can access the service at no cost. Distribution partners include mail-order specialty pharmacies and in-office integrated pharmacies. ModoScript is committed to improving patient outcomes and ensuring equitable access to high-quality care, regardless of patients' backgrounds or socioeconomic status.

Uniphage

Non Equity Assistance in 2021
Uniphage is a biotechnology company that specializes in developing innovative solutions to combat bacterial infections, with a focus on agriculture. It combines the power of bacteriophages, naturally occurring viruses that infect bacteria, with artificial intelligence to create precise and safe antimicrobial products. Uniphage's primary goal is to reduce the use of harmful fungicides, bactericides, and antibiotics in plant agriculture by providing more efficient and eco-friendly alternatives. By using AI algorithms to predict the effectiveness of bacteriophages against specific bacterial infections, Uniphage aims to accelerate the development of new pesticides, thereby minimizing risks to human health and the environment.

Delfina

Non Equity Assistance in 2021
Delfina is a company that specializes in developing a personalized prenatal care system aimed at ensuring the safety of mothers and infants during pregnancy. By leveraging data and machine learning, Delfina's platform creates individualized pregnancy care plans that assess patient risk through various metrics. This approach not only enhances interventional workflows but also improves provider efficiency, facilitating early intervention in prenatal care. Delfina's commitment to data-driven insights is paving the way for clinical innovation, ultimately striving to deliver equitable and cost-effective healthcare solutions for expectant families.

Onye

Non Equity Assistance in 2021
Onye is a health technology company focused on building solutions that power and add value to both patients and healthcare providers. The company's product is a mobile-first web-based electronic health record system for healthcare providers to improve their clinical and administrative workflows.

Therapeutic Vision

Non Equity Assistance in 2021
Therapeutic Vision focuses on the development of pharmaceuticals primarily for the companion animal market and eventually their owners.

US Sleep Apnea

Non Equity Assistance in 2021
US Sleep Apnea aims to combat the increasing Sleep Apnea pandemic by enlisting the help of dentists. Sleep apnea is a developing problem that will kill 48 million individuals prematurely. Dentists are perfectly positioned to solve this need; but, because this is the only medical service a dentist can provide, operational inefficiencies and expensive start-up costs have kept the majority of dentists from delivering care. The US Sleep Apnea platform provides dentists with a digital solution that automates every touchpoint in the patient experience and dramatically saves front office expenditures.

Kinder Digital Pediatric Clinic

Non Equity Assistance in 2021
Kinder is a full-service digital pediatric clinic that combines digital health with concierge care, bringing the pediatrician back to the family's living room.

Glamorous AI

Non Equity Assistance in 2021
Glamorous AI develops an artificial intelligence-based drug discovery platform that focuses on low-data scenarios in pharmaceutical research. The platform utilizes AI to identify and optimize novel chemical compounds, facilitating the discovery of new medicines by analyzing prior experimental results. It is designed to handle sparse, noisy, and small datasets, making it particularly effective for tackling complex drug discovery challenges. By leveraging a large repository of pre-trained and customizable AI models, Glamorous AI enables researchers to screen extensive chemical libraries and address novel and first-in-class therapeutic targets, ultimately driving innovation in drug development and contributing to the advancement of treatments for various diseases.

Akttyva Therapeutics

Non Equity Assistance in 2021
Akttyva Therapeutics specializes in the development of targeted therapeutics aimed at addressing cell barrier dysfunction associated with various vascular disorders. The company leverages a deep understanding of biological pathways, along with advanced artificial intelligence and machine learning techniques, to design solutions that enhance the treatment of these conditions. Through its innovative approach, Akttyva Therapeutics seeks to provide healthcare professionals with effective tools to manage and treat disorders related to cell barriers.

Transcera

Non Equity Assistance in 2021
Transcera is a biotechnology company focused on advancing the treatment of chronic diseases through innovative drug delivery systems. It has developed a novel lipid-based platform that enhances the targeting and absorption of therapeutic molecules, allowing larger drugs to effectively cross cellular barriers. This approach aims to improve the pharmacokinetics of treatments, ultimately benefiting patient outcomes by ensuring that medications are delivered more precisely and efficiently. Transcera's technology represents a significant advancement in drug delivery, addressing critical challenges in the management of chronic conditions.

AcousticaBio

Non Equity Assistance in 2021
AcousticaBio is focused on transforming intravenous medications into formulations suitable for subcutaneous injection. The company has developed a fluid processing technology that creates complex microparticles necessary for these subcutaneous formulations. This innovative approach allows for the conversion of intravenously delivered biologic products into highly concentrated, small-volume injections. By enabling patients to self-administer life-saving drugs with reduced pain and discomfort, AcousticaBio aims to streamline treatment processes, minimizing the need for lengthy hospital visits and enhancing patient convenience.

Free Dynamics

Non Equity Assistance in 2021
Free Dynamics develops innovative electronic temperature sensors that operate without external batteries, leveraging quantum dynamics for enhanced performance. These miniature and cost-effective sensors are designed to be integrated into essential drug vials, ensuring compliance with stringent storage conditions. By providing reliable sensing, recording, and authentication capabilities, Free Dynamics' technology helps the pharmaceutical industry protect against tampering and counterfeiting, thereby facilitating the safe distribution of temperature-sensitive products, including pharmaceuticals and food.

Neurava

Non Equity Assistance in 2021
Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Asan Therapeutics

Non Equity Assistance in 2021
Asan Therapeutics utilizes a novel technology that simplifies the treatment of cancer patients to receive only a single injection instead of several painful injections.

Histofi

Non Equity Assistance in 2021
Histofi is a digital health platform focused on enhancing cancer care through the use of artificial intelligence in diagnostic and treatment processes. The company offers a software-as-a-service (SaaS) platform that integrates advanced technologies with accessible services, particularly tailored for healthcare providers in various regions, including developing countries. Histofi's platform delivers cost-effective and high-quality diagnostic data, which aids physicians in generating interpretable disease scores. This functionality is designed to improve patient outcomes and quality of life, supporting users in achieving their wellness goals. By combining innovative technology with a user-friendly approach, Histofi aims to scale its solutions efficiently to contribute to better cancer care globally.

Stemloop

Non Equity Assistance in 2021
Stemloop is a biotechnology company focused on developing innovative cell-free biosensing products that enhance chemical and molecular testing processes. By utilizing genetically encoded sensing and response mechanisms, Stemloop creates accessible and actionable biosensors that are faster, cheaper, and easier to use than traditional laboratory tests. The company's mission is to address unmet needs in chemical sensing and detection, enabling medical professionals to deliver accurate and timely test results at reduced costs. Through its novel technology, Stemloop aims to unlock the potential of biology to respond effectively to various global challenges.

Fora Health

Non Equity Assistance in 2021
Fora Health helps patients and clinicians track health and take part in shared decision-making. The company's platform links a patient-facing smartphone app with a clinical team web interface, powering remote patient monitoring and shared decision making. Fora Health is scaled to the needs of clinical teams, configuring data collected from validated ePROs and cognitive assessments, to goal tracking, medication adherence, and side effect tracking.

Digi.Bio

Non Equity Assistance in 2021
Digi.Bio is a Netherlands-based company that specializes in developing software solutions for the healthcare industry, particularly in the field of cell therapies. It offers a microfluidic platform that automates repetitive and manual laboratory workflows, utilizing artificial intelligence and electrowetting technology to manipulate droplets at a microscale. This innovative approach aims to streamline multistep liquid handling applications, replacing traditional pipetting methods. Digi.Bio's platform delivers comprehensive analysis of cell therapies, evaluating their performance and outcomes at the single-cell level within 24 hours, while minimizing material waste. By enhancing automation in medical and pharmaceutical settings, Digi.Bio supports the advancement of bioengineering processes.

TissueLabs

Non Equity Assistance in 2021
TissueLabs is the platform for creating organs and tissues in the lab. We offer biomaterials, equipment, and services to support tissue engineering and regenerative medicine. Our products are created to allow performing state-of-the-art research, from drug discovery to organ fabrication. Currently, we are focused on attending the academic life sciences market. In the future, our mission is to fabricate lab-grown tissues and organs, for both research and therapeutic applications.

BioEclosion

Non Equity Assistance in 2021
BioEclosion is a biotechnology company specializing in the development of user-friendly, rapid diagnostic tools. Its core technology, Celifast, is a non-invasive method for detecting celiac disease, validated and patented. The company aims to expand this platform to other emerging diseases, using molecular biomarkers for swift identification. BioEclosion's device comprises a single-use cartridge tailored to each application and a portable, battery-operated reader, making it versatile for human and veterinary health, as well as food and environmental safety.

Spirecut

Non Equity Assistance in 2021
Spirecut is a MedTech company specializing in innovative surgical instruments designed for the treatment of carpal tunnel syndrome and trigger finger. The company has developed a patented technique for ultrasound-guided surgery that eliminates the need for skin incisions, resulting in no post-operative wounds. This approach allows patients to resume daily activities immediately without the need for dressings or coverings on the operated area. Spirecut's instruments represent a significant advancement over traditional methods, improving upon the simple needles typically used by surgeons and radiologists. The enhanced design facilitates the safe release of thickened tissue and aids in preoperative sonographic tracking, ultimately enabling surgeons to achieve better surgical outcomes and accelerating patient recovery.

Babylat

Non Equity Assistance in 2021
Babylat is a developer of an innovative automated medical device designed for the protein enrichment of human milk. This small-scale tabletop device allows for on-site protein extraction in hospitals without the need for expensive laboratory equipment. By concentrating the protein fraction from human milk efficiently and quickly, Babylat's technology ensures that newborn babies receive an adequate supply of protein, which is crucial for their growth and development. The device represents a significant advancement in neonatal care, making essential nutritional support more accessible in various healthcare settings.

BrightCure

Non Equity Assistance in 2021
BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Diagnoly

Non Equity Assistance in 2021
Diagnoly is a medical device company focused on enhancing fetal examination through the use of artificial intelligence. The company has developed an AI-powered plug-in device that allows clinicians to perform ultrasound imaging of human fetuses in real-time. This innovative technology analyzes key fetal biometric parameters, assisting healthcare professionals in identifying complex fetal pathologies and potential pregnancy complications. By streamlining the ultrasound examination process, Diagnoly aims to improve the accuracy and efficiency of fetal health assessments.

BestHealth4U

Non Equity Assistance in 2021
BestHealth4U focuses on the research and development of advanced solutions for manufacturers of class 1 medical devices. The company specializes in medical adhesive technologies that aim to prevent skin injuries, accelerate healing, and enhance overall patient health. Its innovative and environmentally friendly adhesive products are designed to safeguard patients from skin damage, discomfort, irritation, and infections by improving the attachment of bandages, dressings, and medical devices to the skin. By providing effective solutions, BestHealth4U assists healthcare providers in reducing medical adhesive-related skin injuries and promoting the well-being of patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.